Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRL3-Zumab in Solid Tumors
NCT07541001Phase 2Active, not recruiting
- Sponsor
- Intra-ImmuSG
- Start
- Aug 2021
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of PRL3-zumab in solid tumor, sponsored by Intra-ImmuSG. Started Aug 2021; status: active, not recruiting.
02
Drugs
PRL3-zumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07541001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07541001.